Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes IPED2015, a drug candidate which is in clinical phase 2a for the treatment of organic erectile dysfunction; IP2018, a monoamine reuptake inhibitor completed Phase IIa for the treatment of psychogenic erectile dysfunction primarily targeting the serotonin followed by the dopamine system; and IPTN2021, a Phase 1 clinical drug program targeting an orphan drug indication in severe neuropathic pain, and trigeminal neuralgia. The company also developing IP2017, a proprietary triple reuptake inhibitor; and IP2016, a preclinical development for the treatment of depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
तुलना करने के लिए मीट्रिक्स | INIT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधINITपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −20.1x | −1.9x | −0.5x | |
PEG अनुपात | - | −0.04 | 0.00 | |
क़ीमत/बुक | 19.0x | 1.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 8.4x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 216.1% | 526.4% | 45.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.3% | 8.6% | अनलॉक करें |